AbbVie Acquires Apogee Therapeutics in $10.9 Billion Biotech Buyout
The latest in this situation
How it started
What happened
AbbVie announced it acquired biotech Apogee Therapeutics for $10.9 billion, marking its largest buyout in more than five years. The deal grants AbbVie access to zumilokibart, an experimental treatment targeting inflammatory diseases like atopic dermatitis and asthma. This acquisition is part of a trend where pharmaceutical companies are pursuing mergers and acquisitions to build portfolios before key patents expire on major treatments.
Why it matters
The acquisition underscores the surge in pharmaceutical dealmaking as companies seek new growth drivers to offset the loss of exclusivity for legacy drugs like Humira, Skyrizi, and Rinvoq. This strategic move helps AbbVie strengthen its next-generation immunology pipeline.
Who's involved
- AbbVieExecuted the $10.9 billion acquisition of Apogee Therapeutics to strengthen its immunology pipeline.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- AbbVieSpeculative
AbbVie could see increased revenue potential from zumilokibart, which addresses a large and growing atopic dermatitis market.
- SanofiSpeculative
Sanofi might face reduced sales in the atopic dermatitis market due to the introduction of AbbVie's new drug.
- Eli Lilly and CompanySpeculative
Eli Lilly and Company might face increased competition for market share in the pharmaceutical sector.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- SEC oversight increases as AbbVie acquires Apogee TherapeuticsSEC oversight increases as AbbVie completes $10.9 billion acquisitionLikely
- AbbVie's pipeline growth could strengthen partnership with GenmabAbbVie's pipeline boost may increase the strategic value of its partnership with GenmabPossible
- AbbVie's acquisition may increase FDA drug application volumeAbbVie's pipeline expansion could increase the volume of drug applications reviewed by the FDA.Possible
- AbbVie acquisition strengthens pipeline, potentially boosting Norges Bank's stakeNorges Bank's holdings in AbbVie could see a boost from major pipeline acquisitionPossible
- AbbVie's immunology expansion may increase competitive pressure on AmgenAbbVie's acquisition of Apogee could intensify competition for Amgen in immunologyPossible
See all 7 possible ripples
- AbbVie's pipeline expansion may increase competitive pressure on AstraZenecaAbbVie's new pipeline growth may increase competitive pressure on AstraZenecaPossible
- How could AbbVie's acquisition of Apogee Therapeutics affect Eli Lilly and Company?AbbVie's acquisition may intensify competition in immunology marketPossible
How it developed
Newest first. Tap a step to see who reported it.- AbbVie is developing ABBV-466, a potential successor to Skyrizi, whose patents may expire by 2033.Sub-event
- M&A activity is driving sector recovery.Sub-event
- The competitive landscape heats up as Sanofi's Dupixent faces challenges from AbbVie's new drug and Zumilokibart.Sub-event
AbbVie is focusing on pipeline growth and alternatives to Dupixent amid drug exclusivity challenges.1 source
AbbVie is leveraging acquisitions, including Apogee Therapeutics, to bolster its next-generation immunology pipeline while competing in the atopic dermatitis market and managing Humira's patent expiry.1 source
AbbVie executes major acquisition of Apogee Therapeutics.1 source
- AbbVie and Eli Lilly are competing in the pharmaceutical market.Sub-event
Keep exploring
The entities involved
-
AbbVie
pharmaceutical company
-
HUMIRA
Czech company
-
Sanofi
French pharmaceutical company
Nothing else this week.
Related events
- Canandaigua National Trust Co of Florida bought a new stake in AbbVie shares and granted Breakthrough Therapy Designations for one of its drugs.
- AbbVie products are succeeding Humira in the market, while FDA approvals and Fed caution influence market expectations.
- Bristol-Myers Squibb and AbbVie secured regulatory approval for a therapy in the US.
- A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.
- AbbVie, Boehringer Ingelheim, and Pfizer were present at a clinical conference in Las Vegas.